Biosim­i­lar ap­provals on the rise af­ter a two-year slump — Am­gen re­port

Am­gen es­ti­mates that biosim­i­lars re­sult­ed in $3.2 bil­lion in sav­ings last quar­ter alone, ac­cord­ing to its lat­est trend re­port. And though the last two years saw a de­cline in over­all ap­provals, the num­ber of pro­grams in de­vel­op­ment — and the up­take of avail­able biosim­i­lars — is on the rise.

The team at Am­gen took a deep­er look at the US FDA’s 39 ap­proved biosim­i­lars — cheap­er treat­ments that are just as safe and ef­fec­tive as their cost­ly orig­i­nal bi­o­log­ics — and those still in de­vel­op­ment in its ninth an­nu­al trend re­port.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER